HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2005; **20**: 607–608.

Author Index

Ahn, Y.-M., 41
Aksaray, S., 473
Al-tawarah, Y., 141
Aliyev, N. A., 591
Aliyev, Z. N., 591
Allain, H., 511
Allgulander, C., 3
Altman, C., 573
Andersen, H. F., 349
Apel, S., 105
Arango, C., 237
Arias, F., 435
Asghar, S. J., 87
Aubin, H.-J., 511
Austin, C., 3
Aydemir, Ç., 473

Bækdal, T., 349
Baldessarini, R. J., 355, 485
Baldwin, D. S., 533
Barrett, P. R., 287
Basterzi, A. D., 473
Belgamwar, R., 141
Bell, E. C., 87, 415
Benazzi, F., 27
Berger, T., 291
Berk, M., 1, 215, 305
Bernardo, M., 237
Block, R. A., 275
Bodner, T., 291
Bolitschek, J., 359
Bonanni, E., 125
Borkowska, A., 409
Bothma, T., 367
Bourin, M., 15
Bruck, D., 105
Bunevicius, R., 33
Burt, T., 3

Callaway, J., 467
Carrasco, J. L., 435
Caveney, A. F., 263
Centorrino, F., 355, 485
Chaudhry, I., 175
Christopher, G., 47
Cignoni, F., 125
Cimbolli, P., 355
Cincotta, S. L., 485
Cobo, J., 425
Colis, P., 189
Cooper, A., 105
Corkery, J., 343
Crevits, L., 67
Cross, M., 175
Curran, S., 216

Dave, S., 87, 415
de Nayer, A., 573
Deluca, P., 343
Díaz, M., 435
Dib, M., 511
Dodd, S., 1, 305
Donda, P., 401
Dursun, S., 447

Egami, H., 243
Ejsing, T. B., 149, 493
Entner, T., 291

Favre, J.-D., 511
Feltner, D., 263
Ferrando, L., 435
Fisk, J. E., 115
Fleischhacker, W. W., 291, 583
Fogarty, K. V., 355, 485
Folgierini, M., 133
Frey, B. N., 133
Frija-Orvoen, E., 511
Frittelli, C., 125

Garcia-Acosta, S., 511
Gelli, A., 125
Ghicopulos, I., 125
Ghodse, A. H., 343
Gibert, K., 425
Gillet, C., 511
Gillman, P. K., 61
Gilvarry, E., 343
Giordani, B., 263
Girdler, S. S., 33
Göka, E., 473
Golser, K., 583
Goto, M., 243
Graetzhofer, E., 359
Gruber, R. P., 275
Guitton, B., 15
Guzzetta, F., 485

Haddad, P., 447
Haidekker, A., 583
Hakko, H., 467
Halonen, P., 467
Harry, R. D. J., 183
Hartley, L. R., 193
Harvey, B. H., 367
Hashimoto, K., 522
Hauser, P., 211
Hennen, J., 485
Hesselink, J. M. K., 521
Hinderliter, A. L., 33
Hindmarch, I., 501
Hodgson, R., 141
Holloway, F., 207
Holloway, S. R., 55
Holzinger, B., 359
Holzner, B., 65
Horikawa, E., 501
Horne, J. A., 287
Hudson, J. I., 327
Hwang, S. S., 41

Ibáñez, Á., 435
Inokuchi, T., 501
Irmansyah, 573
Isaac, M., 207, 207
Iudice, A., 125
Iudice, G., 125

Jones, A. M., 573
Joyce, P. R., 63
Jung, H.-Y., 41

Kainuma, M., 213
Kajdasz, D. K., 327
Kaji, K., 243
Kakihara, S., 243
Kapczinski, F., 133
Kapfhammer, G., 359
Kato, M., 501
Katschnig, H., 359
Kemmler, G., 291
Kemmler, G.,583
Kennedy, G. A., 105
Kennedy, M. A., 63
Kermadi, I., 511
Kim, H., 309
Kim, J.-H., 41
Kim, J.-M., 97
Kim, S.-C., 41
Kim, S.-W., 97
Kim, Y.-S., 41
Kisa, C., 473
Kohara, K., 243
Kopp, M., 65
Korchounov, A., 203
Kosar, H., 3

Copyright © 2005 John Wiley & Sons, Ltd.

Kunze, M., 359
Kurzthaler, I., 291
Kurzthaler, I., 583

Lader, M., 215, 349
Lambert, O., 15
Langer, P., 65
Larmo, I., 573
Lee, H., 97
Lejoyeux, M., 511
Leonard, B. E., 70, 71, 73, 295, 449, 595, 596, 597, 598
Li, S. C., 459
Light, K. C., 33
Lindenbauer, B., 573
Linnet, K., 149, 493
Loftis, J. M., 211

Machado-Vieira, R., 133
MacKenzie, G., 141
Maeda, H., 243
Magnet, W., 65
Mallinckrodt, C. H., 327
Martynov, O. V., 327
Maruff, P., 263
Mayers, A. G., 533
McDonald, E., 175
McGrath, B. M., 309
Mesías, B., 189
Milani, R. M., 249
Miller, P., 175
Mochizuki, H., 501
Montes, J. M., 435
Montgomery, C., 115
Moss, S. C., 391, 561
Murphy, P., 115
Murri, L., 125

Nakamura, J., 243, 477
Nanez, J. E., 55
Nathan, P. J., 69, 163
Nel, A., 367
Nicoletti, M., 133
Ninomiya, H., 243

Oechsner, M., 203
Oei, A., 193
Oyefeso, A., 343

Parrott, A. C., 249
Pavlic, M., 583
Payen, A., 511
Pedersen, A. D., 493
Pedersen, C. A., 33
Pelegrín, C., 435
Pendlebury, J., 447
Peris, L., 189
Pilowsky, L., 175
Platz, T., 573
Popovic, R., 359
Prause, W., 359
Prieto, A., 189

Räsänen, P., 467
Ravindran, A., 3
Reyner, L. A., 287
Ridout, F., 501
Rieder, A., 359
Rittmannsberger, H., 573
Roberts, R. L., 63
Rodriguez-Cano, E., 425
Rojo, J. E., 425
Rosa, J., 189
Rosenberger, A., 359
Rossi, A., 401, 401
Rybakowski, J. K., 409

Saadeh, M. G., 485
Saiz-Ruiz, J., 435
Sakurada, Y., 501
Saletu, B., 359
Salvatore, P., 355, 485
Sani, G., 355, 485
Schifano, F., 249, 343
Segrave, R., 163
Seitz, A. R., 55
Shin, I.-S., 97
Shinkai, K., 243, 477
Silverstone, P. H., 87, 309, 415
Simpson, S. A., 391, 561
Smith, A. P., 391, 441, 561
Smith, A., 47
Snyder, P. J., 263
Soares, J. C., 133
Sperner, G., 583
Sperner-Unterweger, B., 583
Stanley, J. A., 133
Stein, D. J., 367
Steiner, M., 3
Storvik, M., 467
Stratta, P., 401
Strickland, P., 175
Sutherland, D., 47
Szerman, N., 189

Talamo, A., 485
Tan, C. H., 459
Tashiro, M., 501
Taylor, M., 175
Tiihonen, J., 467
Toyohira, Y., 477
Tribl, G. G., 359
Trimble, M., 74
Turner, J. J. D., 249
Tuzer, V., 473

Ueda, N., 243
Ueno, S., 477

Vallejo, J., 425
Vicente, F., 435
Vieta, E., 225
Viñas, R., 435

Wadsworth, E. J. K., 391, 561
Wambacher, M., 583
Wareing, M., 115
Watanabe, T., 55
Watkin, J. G., 327
Weber, M., 511
Wegener, G., 367
Werth, J., 263
Willson, M. C., 87, 415
Wilman, A. H., 87, 415
Windhager, E., 573
Wissel, J., 291
Wohlreich, M. M., 327

Xie, F., 459

Yamada, Y., 243
Yanagihara, N., 477
Yanai, K., 501
Yang, S.-J., 97
Yazici, K., 473
Yoon, J.-S., 97
Yoshimura, R., 243, 477

Zakzanis, K. K., 183
Zeitlhofer, J., 359
Ziolkowska-Kochan, M., 409

Copyright © 2005 John Wiley & Sons, Ltd.

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2005; **20**: 609–610.

Keyword Index

5-HT, 467
3-methoxy-4-hydroxyphenylglycol (MHPG), 243

accident, 583, 595
accidents, 391
accidents at work, 441
acetylcholinesterase inhibitors, 409
actigraphy, 105
acute mania, 15
adrenal medullary cell, 477
aggression, 237, 249
agitation, 27
akathisia, 41
alcohol, 125, 287, 511, 583, 595
alcohol hallucinosis, 591
alertness, 441
alprazolam, 263
Alzheimer's, 183
Alzheimer's disease, 409
anorexia nervosa, 309
antidepressant augmentation, 163
antidepressants, 163, 473, 533
antihistamines, 501
antipsychotic, 355
antipsychotic agents, 41
antipsychotic dosing, 355
antipsychotics, 15, 485
anxiety, 3, 309
Asia, 459
attention, 275
atypical antipsychotic, 573
atypical antipsychotics, 175, 207, 447
augmentation, 163

benzodiazepines, 391, 583
bipolar disorder, 133, 225, 309, 415, 485
bipolar II disorder, 27
blood–brain barrier, 149, 493
BOLD, 415
bulimia nervosa, 309
buprenorphine, 343

caffeine, 47, 193, 275, 441
cannabis, 249
Cannabis use, 207
car driving, 501
cellular phone, 501
cGMP, 367
change analysis, 263
circadian rhythm, 287
circannular, 467
citalopram, 349
clonidine, 33
clozapine, 141
cocaine dependence treatment, 189
cognition, 401
cognitive dysfunctions, 409
cognitive failures, 441
cognitive function, 97, 263, 501
cognitive performance, 193, 561
combination, 485
critical flicker fusion, 55
cyamemazine, 511
cyclosporine A, 493
cytokines, 473

depression, 27, 97, 163, 435
desipramine binding, 477
dextro-amphetamine, 87
diazepam, 511
diurnal, 105
donepezil, 183, 409
dorsolateral prefrontal cortex, 133
driving, 287
driving ability, 291
drug addiction, 343
drug mortality, 343
drug related deaths, 343
drug–drug interaction, 493
drug–drug interactions, 149
duloxetine, 327
duration judgement, 275

ecstasy, 115, 249
efficacy, 573
escitalopram, 349
expectancy, 193

fast response, 425
fexofenadine, 501
frontal tests, 409
functional magnetic resonance imaging (fMRI), 87
functional magnetic resonance imaging, 415

galantamine, 183
gender differences, 3
glycine, 591

hands-free cell phone, 125
health-related quality of life, 359
healthy volunteers, 125
homovanillic acid (HVA), 243
hostility, 237
hSERT, 467
human psychophysics, 55
human volunteers, 87, 415
hydroxyzine, 501

IL-6, 473
inhibitory amino acid neurotransmitter, 591
injuries, 391
inpatient, 355

lithium, 87, 415
Liverpool University Neuroleptic Side-Effect Rating Scale, 41
long-term outcome, 141

MADRS, 349
magnetic resonance spectroscopy, 309
major depressive disorder, 309, 327, 473
mania, 133
MDMA, 115, 249
mdr1a knock-out mice, 493
memantine, 367
memory, 561
mental health, 391
message, 193
meta-analysis, 183

Copyright © 2005 John Wiley & Sons, Ltd.

metabolism, 207
methylphenidate, 97
mirtazapine, 425, 435
mood, 47, 105
mood disorders, 133
mood stabilizers, 225
motor activity, 105
myo-inositol, 309

nabilone, 291
narcolepsy, 105
naturalistic, 435
naturalistic studies, 141
neuroimaging, 133
neuroleptic, 203
neuroleptics, 511
NFK-β, 367
nitric oxide, 367
NMDA receptor, 367
noradrenergic function, 189
norepinephrine uptake, 477
normothymic agents, 15
nortriptyline, 149, 493

obsessive-compulsive disorder, 309
olanzapine, 141, 355, 401, 477
onset of action, 425

P-glycoprotein, 149, 493
panic disorder, 309
paranoia, 249
Parkinson's disease, 203
parkinsonism, 41
path analysis, 237
perceptual experience, 55
perceptual learning, 55
pharmacology, 183
pindolol, 163
placebo, 193
plasma level, 583
polypharmacy, 355, 485
polytherapy, 485
premenstrual dysphoric disorder, 33
prescribing pattern, 355, 459
prescription cost analysis, 343
prolonged wakefulness, 125
prospective timing, 275
proton magnetic resonance spectroscopy, 133
psychomotor performance, 47
psychopharmacology, 47
psychosis, 203, 447
PTSD, 367

QLI-German, 359
quality of life index, 359
quality of life, 175, 401
quetiapine, 225, 237, 573

randomised-controlled trials, 533
reaction time, 441
Reboxetine, 189
regional cerebral blood flow, 87
relapse prevention, 175
representative survey, 359
reuptake, 467
review, 533
risperidone liquid, 243
risperidone, 141, 493
rivastigmine, 409

safety, 327, 459
schizophrenia, 141, 175, 207, 237, 243, 309, 401, 485, 573
seizures, 343
selective serotonin re-uptake inhibitors, 163
selective serotonin reuptake inhibitors, 459
serotonin, 163
sertraline, 3, 97
sexual dysfunction, 435
sildenafil, 367
simulated driving, 125
sleep, 533
sleep problems, 349
sleepiness, 287
social indicators, 359
social reintegration, 175
sodium valproate, 87
somatization, 249
spatial attention, 415
spatial working memory executive functions, 115
SSRI, 163
SSRIs, 391, 561
stimulants, 105
stress, 367
suicide, 27

tolerability, 327, 573
traumatic brain injury, 97
treatment, 203
treatment of mania, 15
tricyclics, 391
typical antipsychotics, 447

uptake, 467

valproate, 415
verbal fluency, 415
violence, 467

WCST, 401
weight gain, 207, 447
weight management, 447
working memory, 415

ziprasidone, 203
zotepine, 477

Copyright © 2005 John Wiley & Sons, Ltd.

CONTENTS

Volume 20 Issue Nos 1–8

HUMAN PSYCHOPHARMACOLOGY

Issue No.1 January 2005

Editorial
Antidepressants and adolescents: the bipolar confound?: **M. Berk and S. Dodd** 1

Research Article
Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder: **M. Steiner, C. Allgulander, A. Ravindran, H. Kosar, T. Burt and C. Austin** 3

Review
Treatment of acute mania – from clinical trials to recommendations for clinical practice: **M. Bourin, O. Lambert and B. Guitton** 15

Short report
Suicidal ideation and bipolar-II depression symptoms: **F. Benazzi** 27

Research Articles
Lack of beneficial effects of clonidine in the treatment of premenstrual dysphoric disorder: results of a double-blind, randomized study: **R. Bunevicius, A. L. Hinderliter, K. C. Light, C. A. Pedersen and S. S. Girdler** 33

Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia: **H.-Y. Jung, J.-H. Kim, Y.-M. Ahn, S.-C. Kim, S. S. Hwang and Y.-S. Kim** 41

Effects of caffeine in non-withdrawn volunteers: **G. Christopher, D. Sutherland and A. Smith** 47

Visual experience can substantially alter critical flicker fusion thresholds: **A. R. Seitz, J. E. Nanez, S. R. Holloway and T. Watanabe** 55

Letters to the Editor 61

Book Reviews 69

Current Awareness 75

Issue No.2 March 2005

Research Articles
Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation: **E. C. Bell, M. C. Willson, A. H. Wilman, S. Dave, S. J. Asghar and P. H. Silverstone** 87

Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury: **H. Lee, S.-W. Kim, J.-M. Kim, I.-S. Shin, S.-J. Yang and J.-S. Yoon** . . 97

Diurnal actigraphy and stimulant efficacy in narcolespy: **D. Bruck, G. A. Kennedy, A. Cooper and S. Apel** 105

Visuo-spatial working memory deficits in current and former users of MDMA ('ecstasy'): **M. Wareing, J. E. Fisk, P. Murphy and C. Montgomery** 115

Effects of prolonged wakefulness combined with alcohol and hands-free cell phone divided attention tasks on simulated driving: **A. Iudice, E. Bonanni, A. Gelli, C. Frittelli, G. Iudice, F. Cignoni, I. Ghicopulos and L. Murri** 125

A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania: **B. N. Frey, M. Folgierini, M. Nicoletti, R. Machado-Vieira, J. A. Stanley, J. C. Soares and F. Kapczinski** 133

The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire: **R. Hodgson, R. Belgamwar, Y. Al-tawarah and G. MacKenzie** 141

Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier: **T. B. Ejsing and K. Linnet** 149

Current Awareness 155

Issue No.3 April 2005

Review Articles

Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression: **R. Segrave and P. J. Nathan** 163

Towards consensus in the long-term management of relapse prevention in schizophrenia: **M. Taylor, I. Chaudhry, M. Cross, E. McDonald, P. Miller, L. Pilowsky and P. Strickland** 175

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis: **R. D. J. Harry and K. K. Zakzanis** 183

Research Articles

Reboxetine for the treatment of patients with Cocaine Dependence Disorder: **N. Szerman, L. Peris, B. Mesías, P. Colis, J. Rosa and A. Prieto** 189

The effects of caffeine and expectancy on attention and memory: **A. Oei and L. R. Hartley** 193

Case Report

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?: **M. Oechsner and A. Korchounov** 203

Short Report

Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care: **M. Isaac, M. Isaac and F. Holloway** 207

Letters to the Editor

Comments on the paper: 'The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study': **J. M. Loftis and P. Hauser** . . 211

Authors' response: **M. Kainuma** 213

Book Reviews 215

Current Awareness 217

Issue No.4 June 2005

Review Article
Mood stabilisation in the treatment of bipolar disorder: focus on quetiapine: **E. Vieta** 225

Research Articles
The effect of quetiapine on aggression and hostility in patients with schizophrenia: **C. Arango and M. Bernardo** 237

An open study of risperidone liquid in the acute phase of schizophrenia: **R. Yoshimura, J. Nakamura, K. Shinkai, M. Goto, Y. Yamada, K. Kaji, S. Kakihari, N. Ueda, K. Kohara, H. Ninomiya, H. Egami and H. Maeda** 243

Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-related aggression and somatic symptoms: **R. M. Milani, A. C. Parrott, F. Schifano and J. J. D. Turner** 249

A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam: **P. J. Snyder, J. Werth, B. Giordani, A. F. Caveney, D. Feltner, and P. Maruff** 263

Effects of caffeine on prospective duration judgements of various intervals depend on task difficulty: **R. P. Gruber and R. A. Block** 275

Short Report
Early evening low-alcohol intake also worsens sleepiness-related driving impairment: **P. R. Barrett, J. A. Horne and L. A. Reyner** 287

Research Article
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series: **I. Kurzthaler, T. Bodner, G. Kemmler, T. Entner, J. Wissel, T. Berger and W. W. Fleischhacker** . . . 291

Book Reviews 295

Current Awareness 297

Issue No.5 July 2005

Editorial
Antidepressants and the placebo response: **M. Berk and S. Dodd** 305

Review Articles
A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders – focus on magnetic resonance spectroscopy (MRS) studies: **H. Kim, B. M. McGrath and P. H. Silverstone** 309

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trails: **J. I. Hudson, M. M. Wohlreich, D. M. Kajdasz, C. H. Mallinckrodt, J. G. Watkin and O. V. Martynov** 327

Buprenorphine mortality, seizures and prescription data in the UK, 1980—2002: **F. Schifano, J. Corkery, E. Gilvarry, P. Deluca, A. Oyefeso and A. Hamid Ghodse** 343

Research Articles
The effect of escitalopram on sleep problems in depressed patients: **M. Lader, H. F. Andersen and T. Baekdal** 349

Antipsychotic drug use: McLean Hospital, 2002: **F. Centorrino, K. V. Fogarty, G. Sani, P. Salvatore, P. Cimbolli and R. J. Baldessarini** 355

Effects of socio-demographic variables on health-related quality of life determined by the quality of life index – German version: **W. Prause, B. Saletu, G. G. Tribl, A. Rieder, A. Rosenberger, J. Bolitschek, B. Holzinger, G. Kapfhammer, H. Katschnig, M. Kunze, R. Popovic, E. Graetzhofer and J. Zeitlhofer** 359

Involvement of the NMDA receptor, NO-cyclic GMP and nuclear factor K-β in an animal model of repeated trauma: **B. H. Harvey, T. Bothma, A. Nel, G. Wegener and D. J. Stein** 367

Errata 375

Current Awareness 377

Issue No.6 August 2005

Review

Psychotropic medication use and accidents, injuries and cognitive failures: **E. J. K. Wadsworth, S. C. Moss, S. A. Simpson and A. P. Smith** 391

Research Articles

Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study: **P. Stratta, P. Donda, A. Rossi and A. Rossi** 401

One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests: **A. Borkowska, M. Ziolkowska-Kochan and J. K. Rybakowski** 409

Differential effects of chronic lithium and valproate on brain activation in healthy volunteers: **E. C. Bell, M. C. Willson, A. H. Wilman, S. Dave and P. H. Silverstone** 415

Onset of antidepressant action: a pharmacological question?: **J. E. Rojo, K. Gibert, J. Cobo, E. Rodriguez-Cano and J. Vallejo** 425

Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study: **J. Saiz-Ruiz, J. M. Montes, Á. Ibáñez, M. Díaz, F. Vicente, C. Pelegrín, R. Viñas, F. Arias, J. L. Carrasco and L. Ferrando** 435

Review

Caffeine at work: **A. P. Smith** 441

Short Communication

Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results: **J. Pendlebury, P. Haddad and S. Dursun** 447

Book Review

Essential Psychopharmacology: The Prescriber's Guide: **B. E. Leonard** 449

Current Awareness 451

Issue No.7 October 2005

Research Articles

Are they being used safely? A retrospective cross-sectional tertiary health care survey of selective serotonin reuptake inhibitors prescribing practice in Singapore: **F. Xie, C. H. Tan and S. C. Li** 459

Seasonal variations in [^{3}H]citalopram platelet binding between healthy controls and violent offenders in Finland: **J. Callaway, M. Storvik, P. Halonen, H. Hakko, P. Räsänen and J. Tiihonen** 467

IL-6 levels decrease with SSRI treatment in patients with major depression: **A. D. Basterzi, C. Aydemir, C. Kisa, S. Aksaray, V. Tuzer, K. Yazici and E. Göka** 473

Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells: **R. Yoshimura, K. Shinkai, Y. Toyohira, S. Ueno, N. Yanagihara and J. Nakamura** 477

Use of combinations of antipsychotics: McLean Hospital inpatients, 2002: **F. Centrorrino, K. V. Fogarty, G. Sani, P. Salvatore, S. L. Cincotta, J. Hennen, F. Guzzetta, A. Talamo, M. G. Saadeh and R. J. Baldessarini** 485

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied *in vitro*, in knock-out mice and in drug-drug interaction experiments: **T. B. Ejsing, A. D. Pedersen and K. Linnet** 493

Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use: **M. Tashiro, E. Horikawa, H. Mochizuki, Y. Sakurada, M. Kato, T. Inokuchi, F. Ridout, I. Hindmarch and K. Yanai** 501

Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome: **J.-D. Favre, H. Allain, H.-J. Aubin, E. Frija-Orvoen, C. Gillet, M. Lejoyeux, A. Payen, M. Weber, S. Garcia-Acosta, I. Kermadi and M. Dib** 511

Book Review
St. John's Wort and its Active Principles in Depression and Anxiety: **J. M. Keppel Hesselink** 521

Letter to the Editor
Neonatal signs following exposure to SSRIs: **K. Hashimoto** 522

Current Awareness 523

Issue No.8 December 2005

Review
Antidepressants and their effect on sleep: **A. G. Mayers and D. S. Baldwin** 533

Research Articles
SSRIs and cognitive performance in a working sample: **E. J. K. Wadsworth, S. C. Moss, S. A. Simpson and A. P. Smith** 561

Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone: **I. Larmo, A. de Nayer, E. Windhager, Irmansyah, B. Lindenbauer, H. Rittmannsberger, T. Platz, A. M. Jones and C. Altman** 573

Alcohol and/or benzodiazepine use: different accidents – different impacts?: **I. Kurtzhaler, M. Warnbacher, K. Golser, G. Sperner, B. Sperner-Unterweger, A. Haidekker, M. Pavlic, G. Kemmler and W. Fleischhacker** 583

Application of glycine in acute alcohol hallucinosis: **N. A. Aliyev and Z. N. Aliyev** 591

Book Reviews
Human Psychoneuroimmunology: **B. E. Leonard** 595

Clinical Handbook of Psychotropic Drugs: **B. E. Leonard** 596

Evidence Based Medicine, Psychopharmacology: **B. E. Leonard** 597

Neurobiology of Mental Illness: **B. E. Leonard** 598

Current Awareness 599

Author Index 607

Keyword Index 609

Volume Contents iii